Nutra Pharma Corp reported a significant financial turnaround in its 10-K filing for the fiscal year ending December 31, 2022, achieving a net income of $8.2 million compared to a net loss of $13.1 million in 2021. This improvement was primarily driven by a substantial increase in revenue, which rose to $438,274 from $97,735 in the previous year. The company attributed this growth to heightened sales of its products, particularly those manufactured for Avini Health Corporation, a related party. The cost of sales also increased, but the gross profit margin improved to 62.84% from 57.78%, reflecting a decrease in manufacturing costs.
In terms of operational changes, Nutra Pharma has made strides in its manufacturing capabilities, transitioning to in-house production, which is expected to enhance efficiency and reduce costs. The company has also expanded its product offerings, including private label versions of its Nyloxin products, which began distribution in 2021. As of December 31, 2022, Nutra Pharma employed six individuals and continued to seek strategic partnerships to bolster its market presence.
Despite the positive financial results, Nutra Pharma faces ongoing challenges, including a working capital deficit of $12.4 million and a significant accumulated deficit of $73.6 million. The company has indicated that it will require additional financing to sustain operations and fund future growth initiatives. The management has expressed concerns about its ability to continue as a going concern without securing adequate funding or achieving sufficient sales levels.
Looking ahead, Nutra Pharma plans to initiate a Phase I/II clinical study for its lead drug candidate, RPI-78M, targeting pediatric multiple sclerosis, with a goal to commence the study in early 2026. The company is also focused on increasing sales of its existing products and exploring new market opportunities, particularly in international markets. However, the success of these initiatives is contingent upon securing the necessary financing and navigating the competitive landscape of the biopharmaceutical industry.
About NUTRA PHARMA CORP
Nutra Pharma is a biopharmaceutical company specializing in drug discovery, development, and commercialization of treatments for autoimmune, viral, and pain-related conditions. It offers over-the-counter pain relievers, homeopathic products, and drug candidates targeting neurological and infectious diseases. The company focuses on innovative therapies, strategic licensing, and international expansion, leveraging proprietary technology and regulatory designations like Orphan Drug status to address serious health conditions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov